- Home
- OLMA vs ATXS Comparison
OLMA vs ATXS Comparison
Compare OLMA & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- ATXS
- Stock Information
- Founded
- OLMA 2006
- ATXS 2008
- Country
- OLMA United States
- ATXS United States
- Employees
- OLMA N/A
- ATXS N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- ATXS Health Care
- Exchange
- OLMA Nasdaq
- ATXS Nasdaq
- Market Cap
- OLMA 378.9M
- ATXS 424.4M
- IPO Year
- OLMA 2020
- ATXS 2015
- Fundamental
- Price
- OLMA $7.75
- ATXS $7.39
- Analyst Decision
- OLMA Strong Buy
- ATXS Buy
- Analyst Count
- OLMA 5
- ATXS 6
- Target Price
- OLMA $24.00
- ATXS $33.00
- AVG Volume (30 Days)
- OLMA 1.1M
- ATXS 337.6K
- Earning Date
- OLMA 11-11-2025
- ATXS 11-12-2025
- Dividend Yield
- OLMA N/A
- ATXS N/A
- EPS Growth
- OLMA N/A
- ATXS N/A
- EPS
- OLMA N/A
- ATXS N/A
- Revenue
- OLMA N/A
- ATXS N/A
- Revenue This Year
- OLMA N/A
- ATXS N/A
- Revenue Next Year
- OLMA N/A
- ATXS N/A
- P/E Ratio
- OLMA N/A
- ATXS N/A
- Revenue Growth
- OLMA N/A
- ATXS N/A
- 52 Week Low
- OLMA $2.86
- ATXS $3.56
- 52 Week High
- OLMA $13.93
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- OLMA 64.67
- ATXS 57.24
- Support Level
- OLMA $7.49
- ATXS $6.99
- Resistance Level
- OLMA $8.40
- ATXS $7.94
- Average True Range (ATR)
- OLMA 0.67
- ATXS 0.51
- MACD
- OLMA 0.08
- ATXS 0.02
- Stochastic Oscillator
- OLMA 75.63
- ATXS 70.46
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.